This subproject is one of many research subprojects utilizing theresources provided by a Center grant funded by NIH/NCRR. The subproject andinvestigator (PI) may have received primary funding from another NIH source,and thus could be represented in other CRISP entries. The institution listed isfor the Center, which is not necessarily the institution for the investigator.
SPECIFIC AIMS :To evaluate the immunological activity of bi-annual redosing of the CTLA-4 blocking monoclonal antibody CP-675,260 in patients with melanoma and response to prior therapy.
Showing the most recent 10 out of 1085 publications